Contact Us
About
Our Company
Management Team
Board of Directors
Scientific Advisors
Product Candidates
Overview
HONEDRA® (formerly CLBS12)
CLBS14
CLBS16
CLBS119
CLBS03
Our Technologies
Overview
CD34+ Cell Technology
T Regulatory Cell Technology
Publications
Investors
Overview
News
Events
Media Coverage
Corporate Presentation
Fact Sheet
Analyst Coverage
SEC Filings
Stock Information
FAQs
Corporate Governance
Disclosures
Active Clinical Trials
ESCaPE-CMD (CLBS16)
HONEDRA® (formerly CLBS12)
The Sanford Project: T-Rex Study of CLBS03
Caladrius Biosciences CEO outlines key objectives for its cardiovascular programs in 2020
January 15, 2020
For link to original source, please
click here
.
January 15, 2020
January 15, 2020